Personalized risk assessment of heart failure patients: More perspectives from transforming growth factor super-family members

Clinica Chimica Acta

Volumn 443, Issue , 2015, Pages 94-99

  Goletti, S ^a   Gruson, D ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Activin; GDF 11; GDF 15; Heart; Myostatin; Prognosis

Indexed keywords

ACTIVIN A; BIOLOGICAL MARKER; GROWTH DIFFERENTIATION FACTOR 11; GROWTH DIFFERENTIATION FACTOR 15; MYOSTATIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTIVIN; BONE MORPHOGENETIC PROTEIN; GDF11 PROTEIN, HUMAN; GDF15 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR; MSTN PROTEIN, HUMAN;

CARDIAC REMODELING; CARDIOVASCULAR RISK; CLINICAL EVALUATION; HEART DISEASE; HEART FAILURE; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; BLOOD; METABOLISM;

ACTIVINS; BIOMARKERS; BONE MORPHOGENETIC PROTEINS; GROWTH DIFFERENTIATION FACTOR 15; GROWTH DIFFERENTIATION FACTORS; HEART FAILURE; HUMANS; MYOSTATIN; RISK ASSESSMENT;

EID: 84924262097     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.09.014     Document Type: Review

References (83)

1. Braunwald E., Bristow M.R. Congestive heart failure: fifty years of progress. Circulation 2000, 102:IV14-IV23.
2. Yancy C.W., Jessup M., Bozkurt B., et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2013, 62(16):e147-e239.
3. Januzzi J.L., Chen-Tournoux A.A., Moe G. Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. Am J Cardiol 2008, 101:29-38.
4. Jessup M., Brozena S. Heart failure. N Engl J Med 2003, 348:2007-2018.
5. Nichols M., Townsend N., Scarborough P., Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J 2013, 34:3028-3034.
6. Mueller C. Cost-effectiveness of B-type natriuretic peptide testing. Congest Heart Fail 2008, 14:35-37.
7. Volpe M., Rubattu S., Burnett J. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 2014, 35:419-425.
8. Maisel A., Mueller C., Nowak R., et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010, 55:2062-2076.
9. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
10. Mueller T., Dieplinger B., Gegenhuber A., Poelz W., Pacher R., Haltmayer M. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008, 54:752-756.
11. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
12. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992, 20:248-254.
13. Piano M.R., Prasun M. Neurohormone activation. Crit Care Nurs Clin North Am 2003, 15:413-421.
14. Cohn J.N., Ferrari R., Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000, 35:569-582.
15. Emdin M., Vittorini S., Passino C., Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail 2009, 11:331-335.
16. Wollert K.C. Tailored therapy for heart failure: the role of biomarkers. Eur Heart J 2012, 33:2246-2248.
17. Tsuchida K. Activins, myostatin and related TGF-beta family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metabol Disord 2004, 4:157-166.
18. Breitbart A., Auger-Messier M., Molkentin J.D., Heineke J. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am J Physiol Heart Circ Physiol 2011, 300:H1973-H1982.
19. Loffredo F.S., Steinhauser M.L., Jay S.M., et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell 2013, 153:828-839.
20. Sugden P.H., Clerk A. Cellular mechanisms of cardiac hypertrophy. J Mol Med 1998, 76:725-746.
21. Lim H., Zhu Y.Z. Role of transforming growth factor-beta in the progression of heart failure. Cell Mol Life Sci 2006, 63:2584-2596.
22. Paulus W.J., Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013, 62:263-271.
23. Gruson D., Buglioni A., Burnett J.C. PTH: potential role in management of heart failure. Clin Chim Acta 2014, 433:290-296. (Epub;%2014 Apr 1.:290-6). 10.1016/j.cca.2014.03.029.
24. Ruiz-Ortega M., Rodriguez-Vita J., Sanchez-Lopez E., Carvajal G., Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 2007, 74:196-206.
25. Dobaczewski M., Chen W., Frangogiannis N.G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011, 51:600-606.
26. Edgley A.J., Krum H., Kelly D.J. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc Ther 2012, 30:e30-e40.
27. Gray P.C., Greenwald J., Blount A.L., et al. Identification of a binding site on the type II activin receptor for activin and inhibin. J Biol Chem 2000, 275:3206-3212.
28. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
29. Kang J.S., Liu C., Derynck R. New regulatory mechanisms of TGF-beta receptor function. Trends Cell Biol 2009, 19:385-394.
30. ten D P., Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004, 29:265-273.
31. Masaki M., Izumi M., Oshima Y., et al. Smad1 protects cardiomyocytes from ischemia-reperfusion injury. Circulation 2005, 111:2752-2759.
32. McPherron A.C., Lawler A.M., Lee S.J. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997, 387:83-90.
33. Sharma M., Kambadur R., Matthews K.G., et al. Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct. J Cell Physiol 1999, 180:1-9.
34. Biesemann N., Mendler L., Wietelmann A., et al. Myostatin regulates energy homeostasis in the heart and prevents heart failure. Circ Res 2014, 115:296-310.
35. Bish L.T., George I., Maybaum S., Yang J., Chen J.M., Sweeney H.L. Myostatin is elevated in congenital heart disease and after mechanical unloading. PLoS One 2011, 6:e23818.
36. Shyu K.G., Lu M.J., Wang B.W., Sun H.Y., Chang H. Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur J Clin Invest 2006, 36:713-719.
37. George I., Bish L.T., Kamalakkannan G., et al. Myostatin activation in patients with advanced heart failure and after mechanical unloading. Eur J Heart Fail 2010, 12:444-453.
38. Gruson D., Ahn S.A., Ketelslegers J.M., Rousseau M.F. Increased plasma myostatin in heart failure. Eur J Heart Fail 2011, 13:734-736.
39. Gaussin V., Depre C. Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res. 2005, 68(3):347-349.
40. Wang B.W., Chang H., Kuan P., Shyu K.G. Angiotensin II activates myostatin expression in cultured rat neonatal cardiomyocytes via p38 MAP kinase and myocyte enhance factor 2 pathway. J Endocrinol 2008, 197:85-93.
41. Gaussin V., Depre C. Myostatin, the cardiac chalone of insulin-like growth factor-1. Cardiovasc Res 2005, 68:347-349.
42. Gruson D., Ginion A., Lause P., Ketelslegers J.M., Thissen J.P., Bertrand L. Urotensin II and urocortin trigger the expression of myostatin, a negative regulator of cardiac growth, in cardiomyocytes. Peptides 2012, 33:351-353.
43. Morissette M.R., Cook S.A., Foo S., et al. Myostatin regulates cardiomyocyte growth through modulation of Akt signaling. Circ Res 2006, 99:15-24.
44. McKoy G., Bicknell K.A., Patel K., Brooks G. Developmental expression of myostatin in cardiomyocytes and its effect on foetal and neonatal rat cardiomyocyte proliferation. Cardiovasc Res 2007, 74:304-312.
45. Tsuchida K., Nakatani M., Hitachi K., et al. Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 2009, 18:7-15.
46. Wei Q., Wang Y.N., Liu H.Y., et al. The expression and role of activin A and follistatin in heart failure rats after myocardial infarction. Int J Cardiol 2013, 168:2994-2997.
47. Venteclef N., Guglielmi V., Balse E., et al. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur Heart J 2013, [Mar 22; epub ahead of print].
48. Chen Y., Rothnie C., Spring D., et al. Regulation and actions of activin A and follistatin in myocardial ischaemia-reperfusion injury. Cytokine 2014, 69:255-262.
49. Yndestad A., Ueland T., Oie E., et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation 2004, 109:1379-1385.
50. Oshima Y., Ouchi N., Shimano M., et al. Activin A and follistatin-like 3 determine the susceptibility of heart to ischemic injury. Circulation 2009, 20:1606-1615.
51. Mahmoudabady M., Mathieu M., Dewachter L., et al. Activin-A, transforming growth factor-beta, and myostatin signaling pathway in experimental dilated cardiomyopathy. J Card Fail 2008, 14:703-709.
52. Tan S.M., Zhang Y., Connelly K.A., Gilbert R.E., Kelly D.J. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 2010, 298:H1415-H1425.
53. Wollert K.C., Kempf T. GDF-15 in heart failure: providing insight into end-organ dysfunction and its recovery?. Eur J Heart Fail 2012, 14:1191-1193.
54. Kempf T., Wollert K.C. Growth differentiation factor-15: a new biomarker in cardiovascular disease. Herz 2009, 34:594-599.
55. Ho J.E., Mahajan A., Chen M.H., et al. Clinical and genetic correlates of growth differentiation factor 15 in the community. Clin Chem 2012, 58:1582-1591.
56. Rohatgi A., Patel P., Das S.R., et al. Association of growth differentiation factor-15 with coronary atherosclerosis and mortality in a young, multiethnic population: observations from the Dallas Heart Study. Clin Chem 2012, 58:172-182.
57. Anand I.S., Kempf T., Rector T.S., et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010, 122:1387-1395.
58. Lindahl B. The story of growth differentiation factor 15: another piece of the puzzle. Clin Chem 2013, 59:1550-1552.
59. Souza T.A., Chen X., Guo Y., et al. Proteomic identification and functional validation of activins and bone morphogenetic protein 11 as candidate novel muscle mass regulators. Mol Endocrinol 2008, 22:2689-2702.
60. Patel V.K., Demontis F. GDF11/myostatin and aging. Aging (Albany NY) 2014, 6:351-352.
61. Tsuchida K. Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel 2008, 11:487-494.
62. Han H.Q., Zhou X., Mitch W.E., Goldberg A.L. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol 2013, 45:2333-2347.
63. Brandt C., Nielsen A.R., Fischer C.P., Hansen J., Pedersen B.K., Plomgaard P. Plasma and muscle myostatin in relation to type 2 diabetes. PLoS One 2012, 7:e37236.
64. Chen W.J., Greulich S., van der Meer R.W., et al. Activin A is associated with impaired myocardial glucose metabolism and left ventricular remodeling in patients with uncomplicated type 2 diabetes. Cardiovasc Diabetol 2013, 12:12-150.
65. Greulich S., Maxhera B., Vandenplas G., et al. Secretory products from epicardial adipose tissue of patients with type 2 diabetes mellitus induce cardiomyocyte dysfunction. Circulation 2012, 126:2324-2334.
66. Hellemons M.E., Mazagova M., Gansevoort R.T., et al. Growth-differentiation factor 15 predicts worsening of albuminuria in patients with type 2 diabetes. Diabetes Care 2012, 35:2340-2346.
67. Wan S.H., Vogel M.W., Chen H.H. Pre-clinical diastolic dysfunction. J Am Coll Cardiol 2014, 63:407-416.
68. Szulc P., Hofbauer L.C., Rauner M., Goettsch C., Chapurlat R., Schoppet M. Serum myostatin levels are negatively associated with abdominal aortic calcification in older men: the STRAMBO study. Eur J Endocrinol 2012, 167:873-880.
69. Schopfer D.W., Ku I.A., Regan M., Whooley M.A. Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study). Am Heart J 2014, 167:186-192.
70. Eggers K.M., Kempf T., Wallentin L., Wollert K.C., Lind L. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013, 59:1091-1098.
71. Wallentin L., Zethelius B., Berglund L., et al. GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. PLoS One 2013, 8:e78797.
72. Vila G., Riedl M., Anderwald C., et al. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients. Clin Chem 2011, 57:309-316.
73. Schaub N., Reichlin T., Twerenbold R., et al. Growth differentiation factor-15 in the early diagnosis and risk stratification of patients with acute chest pain. Clin Chem 2012, 58:441-449.
74. Widera C., Pencina M.J., Bobadilla M., et al. Incremental prognostic value of biomarkers beyond the GRACE (Global Registry of Acute Coronary Events) score and high-sensitivity cardiac troponin T in non-ST-elevation acute coronary syndrome. Clin Chem 2013, 59:1497-1505.
75. Gruson D., Lepoutre T., Ahn S.A., Ketelslegers J.M., Rousseau M.F. Comparison between intact and bioactive parathyroid hormone assays in patients with severe heart failure. Clin Biochem 2013, 46:391-394.
76. Kempf T., Horn-Wichmann R., Brabant G., et al. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. Clin Chem 2007, 53:284-291.
77. Montoro-Garcia S., Hernandez-Romero D., Jover E., et al. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. Eur J Intern Med 2012, 23:169-174.
78. Baessler A., Strack C., Rousseva E., et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. Eur J Heart Fail 2012, 14:1240-1248.
79. Meyer S., Van Der Meer P., van Deursen V.M., et al. Neurohormonal and clinical sex differences in heart failure. Eur Heart J 2013, 34:2538-2547.
80. Wu H., et al. Correlation between blood activin levels and clinical parameters of type 2 diabetes. Exp Diabetes Res 2012, [epub ahead of print].
81. Ueland T., et al. Activin A and cardiovascular disease in type 2 diabetes mellitus. Diabetes Vasc Dis Res 2012, 9:234-237.
82. Breitbart A., Scharf G.M., Duncker D., et al. Highly specific detection of myostatin prodomain by an immunoradiometric sandwich assay in serum of healthy individuals and patients. PLoS One 2013, 8:e80454.
83. Izumiya Y., Hanatani S., Kimura Y., et al. Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction. Can J Cardiol 2014, 30:338-344.